NCT02710890 - Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children. | Biotech Hunter

Enrollment

103

Participants

Timeline

Start Date

May 30, 2017

Primary Completion Date

June 28, 2019

Study Completion Date

June 28, 2019

Conditions

Epilepsy

Interventions

DRUG

Lacosamide

"Pharmaceutical form: solution for infusion~Concentration: 10 mg/ml~Route of Administration: intravenous"

Trial Locations (23)

33470

Ep0060 008, Loxahatchee Groves

35233

Ep0060 003, Birmingham

44308

Ep0060 006, Akron

45229

Ep0060 011, Cincinnati

55101

Ep0060 009, Saint Paul

72202

Ep0060 010, Little Rock

75235

Ep0060 005, Dallas

78258

Ep0060 007, San Antonio

89104

Ep0060 014, Henderson

08903

Ep0060 002, New Brunswick

Unknown

Ep0060 400, Budapest

Ep0060 401, Debrecen

Ep0060 503, Messina

Ep0060 505, Roma

Ep0060 502, Verona

Ep0060 701, Krakow

Ep0060 224, Dnipro

Ep0060 225, Dnipro

Ep0060 220, Ivano-Frankivsk

Ep0060 221, Kiev

Ep0060 222, Kiev

Ep0060 226, Kiev

Ep0060 223, Vinnytsia

All Listed Sponsors

lead

UCB BIOSCIENCES, Inc.

INDUSTRY